Jim L. Allen serves as Independent Director of the Company. He was appointed to our board of directors effective October 1, 2019. Mr. Allen is Chief Executive Officer and President of Sea Star, Inc., a real estate development company, and has served in that capacity since he founded the company in February 1989. Mr. Allen has founded multiple companies from concept to full operation involving the development of various technologies, patents, manufacturing processes, and sales, distribution and maintenance programs. Six of his ventures have resulted in sales to publicly-traded companies. One of his companies was sold to Roper Technologies, Inc. and he is currently serving in a consulting capacity for TransCore Atlantic LLC, a Roper Technologies, Inc. company. He is a named inventor on 29 issued and pending patents. Mr. Allen has studied business at Troy University and Auburn University at Montgomery.
Jim Allen is 64, he's been the Independent Director of BioCardia since 2019. There are 4 older and 9 younger executives at BioCardia. The oldest executive at BioCardia Inc. is Simon Stertzer, 83, who is the Independent Chairman of the Board.
Jim's mailing address filed with the SEC is C/O BIOCARDIA, INC., 320 SOQUEL WAY, SUNNYVALE, CA, 94085.
Over the last 8 years, insiders at BioCardia have traded over $2,555,815 worth of BioCardia stock and bought 6,474,371 units worth $6,325,055 . The most active insiders traders include Phillip Md Et Al Frost Gamm..., Simon H Stertzer и Richard M Krasno. On average, BioCardia executives and independent directors trade stock every 48 days with the average trade being worth of $1,321,186. The most recent stock trade was executed by Phillip Md Et Al Frost Gamm... on 19 January 2024, trading 129,802 units of BCDA stock currently worth $55,815.
we are a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases with large unmet medical needs. biocardia is developing proprietary comprehensive biotherapeutic solutions for cardiovascular disease in its cardiamp™ and cardiallo™ therapies. clinical results supporting both therapeutic programs are compelling and build upon the most rigorous data in the field to date with intramyocardial delivery of marrow-derived cells. these programs are enabled by the company's helix™ transendocardial delivery systems and morph® vascular access products, which are partnered to enable other promising biotherapeutic programs.
BioCardia executives and other stock owners filed with the SEC include: